Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity

Indian Journal of Medical Research

Volumn 129, Issue 1, 2009, Pages 64-67

  Sarda, Pawan ^a   Sharma, S K ^a   Mohan, Alladi ^b   Makharia, Govind ^a   Jayaswal, Arvind ^a   Pandey, R M ^a   Singh, Sarman ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acute; Hepatotoxicity; Treatment; Tuberculosis; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS E VIRUS; HUMAN; JAUNDICE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROSPECTIVE STUDY; SIDE EFFECT; TUBERCULOSIS; VIRUS HEPATITIS; VOMITING;

ADULT; ALANINE TRANSAMINASE; ANTITUBERCULAR AGENTS; ASPARTATE AMINOTRANSFERASES; FEMALE; HEPATITIS, TOXIC; HEPATITIS, VIRAL, HUMAN; HUMANS; INDIA; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TUBERCULOSIS;

EID: 65949106572     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.
2. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9: 2026-30.
3. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-9.
4. Dash LA, Comstock GW, Flynn PG. Isoniazid preventive therapy: retrospect and prospect. Am Rev Respir Dis 1980; 121: 1039-44.
5. Kumar A, Misra PK, Mehotra R, Govil YC, Rana GS. Hepatotoxicity of rifampin and isoniazid. Is it all druginduced hepatitis? Am Rev Respir Dis 1991; 143: 1350-2.
6. Piramanayagam P, Tahir M, Sharma SK, Smith-rohrberg D, Biswas A, Vajpayee M. Persistently high HIV seroprevalence among adult tuberculosis patients at a tertiary care centre in Delhi. Indian J Med Res 2007; 125: 163-7.
7. Turktas H, Unsal M, Tulck N, Orue O. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tuber Lung Dis 1994; 75: 58-60.
8. Acharya SK, Madan K, Dattagupta S, Panda SK. Viral hepatitis in India. Natl Med J India 2006; 19: 203-17.
9. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. TB India 2006. RNTCP Status Report. DOTS for All: All for DOTS. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; 2006. Available at URL: http:// www.tbcindia.org/pdfs/Annual%20Report%20TB%202006.pdf. Accessed on February 8, 2008.
10. Sharma SK, Mohan A, Kadhiravan T. HIV-TB co-infection: epidemiology, diagnosis & management. Indian J Med Res 2005; 121: 550-67.